Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
LAG3 is the most promising immune checkpoint next to PD-1 and CTLA-4. High LAG3 and FGL1 expression boosts tumor growth by inhibiting the immune microenvironment. This review comprises four sections presenting the structure/expression, interaction, biological effects, and clinical application of LAG3/FGL1. D1 and D2 of LAG3 and FD of FGL1 are the LAG3-FGL1 interaction domains. LAG3 accumulates on the surface of lymphocytes in various tumors, but is also found in the cytoplasm in non-small cell lung cancer (NSCLC) cells. FGL1 is found in the cytoplasm in NSCLC cells and on the surface of breast cancer cells. The LAG3-FGL1 interaction mechanism remains unclear, and the intracellular signals require elucidation. LAG3/FGL1 activity is associated with immune cell infiltration, proliferation, and secretion. Cytokine production is enhanced when LAG3/FGL1 are co-expressed with PD-1. IMP321 and relatlimab are promising monoclonal antibodies targeting LAG3 in melanoma. The clinical use of anti-FGL1 antibodies has not been reported. Finally, high FGL1 and LAG3 expression induces EGFR-TKI and gefitinib resistance, and anti-PD-1 therapy resistance, respectively. We present a comprehensive overview of the role of LAG3/FGL1 in cancer, suggesting novel anti-tumor therapy strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · cited 2×
“Moreover, the amount of LAG3PD1 T cells is different in various molecular subtypes of breast cancer, with the highest being in TNBC and lowest in ER/PR breast cancer (8, 28).”
BackgroundHaanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
LAG 3 (CD 223) as a cancer immunotherapy target
Andrews, L. P., Marciscano, A. E., Drake, C. G., & Vignali, D. A. A. (2017) · Immunological Reviews · doi:10.1111/imr.12519 · Cited by 956 · cited 1×
“Lymphocyte-activation gene 3 (LAG3, CD223) is an immune inhibitory checkpoint and is expressed on the surface of lymphocytes (3, 4), such as CD4 T cells, CD8 T cells, natural killer (NK) cells, NK T (NKT) cells, and regulatory T (Treg) cells (5, 6), as well as stored in the lysosomes, which appear on the surface faste…”
BackgroundLAG-3, a novel lymphocyte activation gene closely related to CD4.
Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., & Hercend, T. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.5.1393 · Cited by 925 · cited 1×
“In addition, the hydrophobic leader peptide is encoded by exons I and II, and the highly charged cytoplasmic region is encoded by exon VIII (18).”
BackgroundManagement of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv623 · Cited by 903
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Wang, J., Sanmamed, M. F., Datar, I., Su, T. T., Ji, L., Sun, J., Chen, L., Chen, Y., Zhu, G., Yin, W., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.010 · Cited by 871 · cited 5×
“The downregulation of FGL1 inhibit the growth of MC38 colon cancer cells (43) and SGC-7901 gastric cancer cell (44), especially, in FGL1-KO MC38 colon cancer mouse model, the administration of anti-FGL1 and anti-LAG3 mAbs shows favorable anti-tumor effect, this effect”
BackgroundInfluentialMatsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859 · cited 7×
“When combined with relatlimab and lenalidomide (immunomodulatory drug), the production of IL-2 and NK cellmediated ADCC are enhanced (61).”
BackgroundInfluentialRupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757 · cited 1×
“Except for the monotherapies and combination therapies mentioned above, the gene editing technology CRISPR-Cas9 points out a new direction to enhance the efficacy of tumor immunotherapy, as knocking out PD-1 and LAG3 of CAR-T cells can significantly enhance the anti-tumor effect and inhibit the immunosuppressive micro…”
Background
Cited by
LAG-3 as the third checkpoint inhibitor
Aggarwal, V., Workman, C. J., & Vignali, D. A. A. (2023) · Nature Immunology · doi:10.1038/s41590-023-01569-z · Cited by 341
Huo, J.-L., Wang, Y.-T., Fu, W.-J., Lu, N., & Liu, Z.-S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956090 · Cited by 176
“High level of LAG-3 in kidney renal clear cell carcinoma, non-small cell lung cancer (NSCLC), primary central nervous system lymphoma (PCNSL), hepatocellular carcinoma (HCC) and muscle invasive bladder cancer (MIBC) indicates a poor prognosis, whereas in gastric carcinoma and melanoma predicts a better prognosis (12).”
Background
Metadata
- Authors
- Shi, A.-P., Tang, X.-Y., Xiong, Y.-L., Zheng, K.-F., Liu, Y.-J., Shi, X.-G., Lv, Y., Jiang, T., Ma, N., & Zhao, J.-B.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-01-17
- Volume
- 12
- Pages
- 785091-785091
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4206494082
- Cited by
- 185
- References
- 97
- FWCI
- 14.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.